Where is HALOZYME THERAPEUTICS headquartered?

HALOZYME THERAPEUTICS, INC. is recorded with headquarters in San Diego, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is HALOZYME THERAPEUTICS publicly traded?

Yes — HALOZYME THERAPEUTICS is listed as a public company with ticker HALO on NYSE in SEC EDGAR-derived records.

What drugs are associated with HALOZYME THERAPEUTICS?

We link 1 drug profile(s) where HALOZYME THERAPEUTICS appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is HALOZYME THERAPEUTICS sponsoring?

HALOZYME THERAPEUTICS is linked to 45 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list HALOZYME THERAPEUTICS as applicant?

70 USPTO PatentsView record(s) name HALOZYME THERAPEUTICS, INC. or a normalized variant as applicant.

What pipeline phases does HALOZYME THERAPEUTICS have in our database?

Phase distribution from linked programs: phase 2: 16, phase 1: 14, approved: 11, phase 3: 3.

How many US-approved drugs are linked to HALOZYME THERAPEUTICS?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Where does NovaPharmaNews source data on HALOZYME THERAPEUTICS?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is HALOZYME THERAPEUTICS data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is HALOZYME THERAPEUTICS data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

HALOZYME THERAPEUTICS Pharmaceuticals Company Profile

Name: HALOZYME THERAPEUTICS intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: 12390 El Camino Real, San Diego, California 92130, US
Founded: 2021
Employees: 530
Programs: 45
Drugs: 33
Patents: 70

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

HALOZYME THERAPEUTICS is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker HALO. Primary therapeutic focus areas include Type 1 Diabetes Mellitus, Dehydration, Pancreatic Ductal Adenocarcinoma, Diabetes Mellitus, NSCLC. NovaPharmaNews links 45 clinical program(s), 1 drug profile(s), and 70 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (16), phase 1 (14), approved (11).

Company snapshot

The DeepTech Health Company

1 approved product(s) across US/EU regulatory metadata.
45 active pipeline program(s) linked via ClinicalTrials.gov.
70 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for HALOZYME THERAPEUTICS. Not investment advice.

Top assets

View drugs (33) View projects (45)

Lead pipeline drugs

5-fu
Marketed / approved
aspart
Marketed / approved
aspirin
approved
atezolizumab
approved

Active clinical programs

Hylenex Pain
Phase 3
Placebo Pancreatic Ductal Carcinoma
Phase 3
Testosterone enanthate Hypogonadism, Male
Phase 3
5-Fluorouracil (5-FU) Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Phase 2

Momentum

Proprietary activity score for HALOZYME THERAPEUTICS.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 48 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

CORCEPT THERAPEUTICS

TA overlap score 33.4
Peer + 0 momentum

Eli Lilly and

TA overlap score 32.4
Peer + 0 momentum

Oncolytics Biotech

TA overlap score 24.6
Peer + 0 momentum

Lisata Therapeutics

TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for HALOZYME THERAPEUTICS.

Jun 8, 2026 Clinical update
1838-009 — Approved
Jun 8, 2026 Clinical update
Testosterone enanthate — Phase 3
Jun 8, 2026 Clinical update
Recombinant human hyaluronidase PH20 (rHuPH20) — Phase 1
Jun 8, 2026 Clinical update
recombinant human hyaluronidase — Approved
Jun 8, 2026 Clinical update
recombinant human hyaluronidase — Approved

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is HALOZYME THERAPEUTICS?

HALOZYME THERAPEUTICS is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker HALO. Primary therapeutic focus areas include Type 1 Diabetes Mellitus, Dehydration, Pancreatic Ductal Adenocarcinoma, Diabetes Mellitus, NSCLC. NovaPharmaNews links 45
Is HALOZYME THERAPEUTICS publicly traded?

Yes. HALOZYME THERAPEUTICS is listed with ticker HALO on NYSE per SEC EDGAR records linked on this profile.
What drugs does HALOZYME THERAPEUTICS develop or market?

We link 33 drug profile(s) where HALOZYME THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/halozyme-therapeutics-inc#company-drugs.
What are the latest developments for HALOZYME THERAPEUTICS?

In the last 12 months our linked public records show 45 trial program update(s) and 2 US patent grant(s) tied to this profile.
What therapeutic areas does HALOZYME THERAPEUTICS focus on?

HALOZYME THERAPEUTICS focuses on Type 1 Diabetes Mellitus, Dehydration, Pancreatic Ductal Adenocarcinoma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Oncology

Immunology